Why is Medpace Holdings (MEDP) stock up today?

Medpace Holdings jumped 14.71% to $605.82 on July 23, 2026 — after reporting second-quarter results that handily topped Wall Street's expectations. Revenue reached $707.3 million, beating the consensus estimate of $689.7 million and marking a 17.2% increase year over year. Earnings per share came in at $4.28, well above the $3.96 analyst estimate. The stronger-than-expected results gave investors confidence that the company's business momentum had returned after a sluggish first quarter.

Beyond the headline beat, two additional factors amplified the move. First, Medpace reported a big bookings beat and an improvement in its book-to-bill ratio (a measure comparing new orders booked versus revenue recognized — a reading above 1.0 signals growth), along with higher backlog conversion, according to Investor's Business Daily and SeekingAlpha. Second, the company raised its full-year revenue and EPS guidance, signaling management's confidence in continued demand for its outsourced clinical development services.

The jump is especially striking given the broader market backdrop. The S&P 500 fell 1.21% and the Nasdaq 100 (tracked by QQQ) dropped 1.90% on the same day, as Brent crude broke above $100 per barrel, the 10-year Treasury yield hit an 18-month high, and earnings from Alphabet and Tesla revived concerns about AI spending. Medpace's surge against that headwind underscores how company-specific the catalyst was.

As of Thursday's close, Medpace's market capitalization stood at approximately $17.3 billion. The stock gapped up at the open — trading in a range of $592.65 to $677.90 during the session — before settling well above its previous close of $528.12. The share price reflects the market's reaction to what analysts described as a 'standout performance' in the contract research organization (CRO) sector, reversing the first-quarter concerns that had weighed on the stock.